Avacta Group PLC (LON:AVCT) is hosting a science day in February, which will focus on the “rapidly changing nature of oncology treatment being brought about by immunotherapies”.
It will also assess the role that its own Affimer therapeutic platform is playing in this shift in the “therapeutic paradigm”.
READ: Avacta’s Affimer tech gains traction as it clinches deal with “very high-quality partner”
Dr Josep Tabernero, President of the European Society for Medical Oncology and Head of the Val d'Hebron Institute of Oncology, Barcelona, will give the plenary presentation reviewing the progress made in cancer immunotherapies and the challenges that still remain.
Meanwhile, Bill Bachovchin, Professor of Molecular and Chemical Biology at Tufts University School of Medicine, in the US, will discuss the potential for the revolutionary, immuno-oncology active, drug conjugate platform being developed in collaboration between Avacta and Tufts.
Avacta’s recently appointed chief medical officer, Dr Jose Saro, will discuss how the benefits of immunotherapies can be extended to more patients and the particular role that the Affimer platform is playing in this cancer treatment revolution. There will also be contributions from the group's chief scientific officer, Dr Amrik Basran, and chief executive, Dr Alastair Smith.
Attendance at the London event, being held on February 14, is by invitation only and all enquiries should be directed to scienceday@avacta.com.